

Special Issue

Therapeutic Potential of Scopolamine and Its Adverse Effect

Message from the Guest Editors

Scopolamine, a tropane alkaloid with strong anticholinergic properties, has been extensively used in medical practice for conditions such as motion sickness, postoperative nausea, and neurological disorders. However, its therapeutic potential is often counterbalanced by adverse effects, including cognitive impairment, neurotoxicity, and a risk of dependency. Ongoing research aims to optimize its clinical applications while minimizing unwanted side effects through innovative drug delivery systems, antioxidant therapies, and neuroprotective agents. This Special Issue welcomes original research articles, reviews, and short communications exploring the pharmacology of scopolamine, with a focus on mitigating its side effects and expanding its therapeutic applications. We also encourage studies investigating natural bioactive compounds, such as flavonoids and polyphenols, in counteracting scopolamine-induced neurotoxicity and cognitive decline.

Guest Editors

Dr. Ion Brinza

Faculty of Sciences, "Lucian Blaga" University of Sibiu, 7–9 Ion Ratiu Street, 550024 Sibiu, Romania

Prof. Dr. Lucian Hritcu

Faculty of Biology, Alexandru Ioan Cuza University of Iasi, Bd. Carol I, No. 11, 700506 Iasi, Romania

Deadline for manuscript submissions

25 October 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/233981

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)